Login
$LUCD
$0.44 -$0.06 (12.5%) Close

Company Executives

$LUCD Management Team

Dr. Lishan Aklog

Chairman of the Board

Chief Executive Officer

Age 59
Compensation $712.0K USD
Sex Male

Mr. Shaun O'Neil

President

Chief Operating Officer

Age 43
Compensation $712.0K USD
Sex Male

Mr. Stanley Lapidus

Independent Vice Chairman of the Board

Age 76
Compensation $188.3K USD
Sex Male

Mr. Dennis Mcgrath

Chief Financial Officer

Age 68
Compensation $637.0K USD
Sex Male

Mr. Michael Gordon

General Counsel

Secretary

Age 51
Compensation $662.0K USD
Sex Male
Directors
8
serving now
Independent
7 of 7
stated in the proxy; 1 not stated
Average tenure
5.6 years
from year joined
CEO also chairs the board
Yes
Lishan Aklog, M.D.
Director Age On board Independent Committees Other public boards Pay Source
Lishan Aklog, M.D.
60 Not stated Not stated None stated PAVmed (Nasdaq: PAVM) Paid as CEO
Stanley N. Lapidus
77 2021
5 years
Independent None stated None stated Not stated
James L. Cox, M.D.
83 2015
11 years
Independent None stated None stated Not stated
Dennis A. Matheis
65 2024
2 years
Independent
audit committee
DarioHealth (Nasdaq: DRIO) Not stated
John R. Palumbo
75 2025
1 year
Independent
audit committee
DarioHealth (Nasdaq: DRIO) Not stated
Jacque J. Sokolov, M.D.
71 2021
5 years
Independent
audit committee
None stated Not stated
Ronald M. Sparks
71 2015
11 years
Independent
audit committee
PAVmed (Nasdaq: PAVM) Not stated
Debra J. White
64 2022
4 years
Independent
audit committee
PAVmed (Nasdaq: PAVM) Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 30, 2026
PAVmed
Approximately $13.8 million and $11.3 million
2025 and 2024

Management services agreement under which PAVmed provides management, oversight, administrative and office space services to the Company for a monthly fee.

With the Company Open in proxy
PAVmed
Owns more than 5% of the stock
Approximately $1.9 million and $2.0 million
2025 and 2024

Payroll and benefit expense reimbursement agreement under which the Company reimburses PAVmed for payroll and benefit-related expenses of the Company's personnel.

With the Company Open in proxy
PAVmed
$350,000
2024

Assignment of patent rights related to the EsoCheck device from PAVmed to the Company, for which the Company paid an assignment fee.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support